Ney Carter Borges: POAF and Long-Term Outcomes After Cardiac Surgery
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Postoperative Atrial Fibrillation (POAF) After Cardiac Surgery.
In a large prospective, multinational cohort (VISION Cardiac Surgery; n = 12,234), new-onset postoperative atrial fibrillation (POAF) occurred in 31.8 percent of patients within 30 days of surgery, confirming its status as the most frequent postoperative complication.
From a prognostic standpoint, POAF was strongly associated with subsequent atrial fibrillation: 6.9 percent versus 0.6 percent, corresponding to an adjusted hazard ratio (aHR) of 11.30 (95 percent CI 8.17–15.70), indicating a more than 10-fold increased risk.
Regarding hard outcomes between 30 days and 1 year:
- The composite of stroke or vascular death occurred in 2.3 percent versus 1.5 percent (aHR 1.32; 95percent CI 0.99–1.77), not reaching statistical significance after adjustment.
- All-cause mortality was significantly higher in POAF patients (3.0 percent versus 1.7 percent), with an aHR of 1.54 (95 percent CI 1.18–2.00).
Importantly, absolute stroke rates remained low (approximately 0.7 percent overall), suggesting that POAF may function more as a risk marker than a direct causal driver of thromboembolic events.
Therapeutic strategies were heterogeneous: only 39.4 percent of POAF patients received oral anticoagulation at discharge, while 48.8 percent were treated with amiodarone, reflecting substantial global variability in management.
Conclusion: POAF is common and clinically meaningful, conferring increased mortality and markedly higher AF recurrence, but with a modest and statistically uncertain impact on thromboembolic outcomes.
These findings highlight the need for individualized risk stratification and more standardized management strategies.”
Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy